DENTSPLY SIRONA (NASDAQ:XRAY) Shares Up 13.3% After Analyst Upgrade

DENTSPLY SIRONA Inc. (NASDAQ:XRAY)’s stock price traded up 13.3% during trading on Friday after Wells Fargo & Company raised their price target on the stock from $12.00 to $13.00. Wells Fargo & Company currently has an equal weight rating on the stock. DENTSPLY SIRONA traded as high as $14.48 and last traded at $14.4060. 4,743,575 shares traded hands during mid-day trading, an increase of 2% from the average session volume of 4,667,831 shares. The stock had previously closed at $12.71.

Several other equities research analysts have also issued reports on XRAY. Robert W. Baird lifted their price target on DENTSPLY SIRONA from $12.00 to $14.00 and gave the company a “neutral” rating in a report on Friday. Mizuho lifted their target price on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the company a “neutral” rating in a research note on Tuesday, January 20th. UBS Group decreased their target price on shares of DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Stifel Nicolaus set a $13.00 price target on shares of DENTSPLY SIRONA in a research note on Thursday, November 6th. Finally, Barclays started coverage on shares of DENTSPLY SIRONA in a research note on Monday, December 8th. They issued an “underweight” rating and a $12.00 price objective for the company. Three investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $14.00.

Insider Buying and Selling at DENTSPLY SIRONA

In related news, Director Gregory T. Lucier sold 82,200 shares of the company’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $11.14, for a total value of $915,708.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 0.50% of the company’s stock.

Key Headlines Impacting DENTSPLY SIRONA

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Company announced a $120 million restructuring to redirect annual savings into a “Return-to-Growth” plan (innovation, clinical and sales investment), eliminated the dividend and said it will redeploy capital toward debt paydown and share repurchases — a clear priority shift that drove buying interest. Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Top-line beat: Q4 net sales of $961M topped Street estimates and rose 6.2% year-over-year, a sign that demand trends held up despite cost issues. Dentsply Sirona’s Q4 CY2025 sales top estimates
• Neutral Sentiment: Analysts nudged price targets higher: Wells Fargo raised its target to $13 with an “equal weight” rating and Robert W. Baird raised its target to $14 with a “neutral” rating — upgrades that signal some analyst confidence but still leave implied downside vs. the current trading level. Analyst Price Target Moves (Benzinga) TickerReport: Baird PT Raise
• Neutral Sentiment: Earnings call and transcripts available for detail — useful for investors who want management commentary on the restructuring, capital allocation and product road map. Earnings Call Transcript
• Negative Sentiment: Reported adjusted EPS of $0.27 missed consensus by $0.01 and the quarter included a GAAP net loss of $146M driven by ~$144M of goodwill/intangible impairments — items that pressure near-term reported profitability. Earnings Miss Coverage (Zacks)
• Negative Sentiment: FY2026 revenue guidance of $3.5B–$3.6B sits below consensus (~$3.7B), signaling a softer top-line outlook even as adjusted EPS guidance of $1.40–$1.50 is roughly in line — the revenue gap is a downside catalyst to monitor. Company Outlook (GlobeNewswire)
• Negative Sentiment: Legal risk: Halper Sadeh LLC has opened a shareholder investigation into possible fiduciary breaches, which could create headline risk and distract management. Halper Sadeh Investigation Notice

Institutional Investors Weigh In On DENTSPLY SIRONA

Large investors have recently modified their holdings of the stock. Eurizon Capital SGR S.p.A. bought a new position in shares of DENTSPLY SIRONA during the 4th quarter worth approximately $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in DENTSPLY SIRONA during the first quarter worth $26,000. Parkside Financial Bank & Trust lifted its holdings in shares of DENTSPLY SIRONA by 620.6% during the second quarter. Parkside Financial Bank & Trust now owns 1,715 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 1,477 shares during the period. Huntington National Bank lifted its holdings in shares of DENTSPLY SIRONA by 292.9% during the third quarter. Huntington National Bank now owns 2,786 shares of the medical instruments supplier’s stock valued at $35,000 after acquiring an additional 2,077 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its stake in shares of DENTSPLY SIRONA by 337.9% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock valued at $35,000 after purchasing an additional 2,122 shares in the last quarter. 95.70% of the stock is currently owned by institutional investors.

DENTSPLY SIRONA Trading Up 15.5%

The firm has a market cap of $2.93 billion, a P/E ratio of -4.89, a price-to-earnings-growth ratio of 0.99 and a beta of 1.01. The company has a current ratio of 1.47, a quick ratio of 0.99 and a debt-to-equity ratio of 1.36. The company’s fifty day moving average price is $12.42 and its two-hundred day moving average price is $12.49.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). The firm had revenue of $961.00 million during the quarter, compared to analyst estimates of $926.40 million. DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 17.62%. DENTSPLY SIRONA’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.26 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, sell-side analysts predict that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current fiscal year.

DENTSPLY SIRONA Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, January 9th. Investors of record on Friday, December 26th were given a dividend of $0.16 per share. The ex-dividend date was Friday, December 26th. This represents a $0.64 dividend on an annualized basis and a yield of 4.4%. DENTSPLY SIRONA’s dividend payout ratio is -14.48%.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.